Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Fitzgerald Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt     Notes payable, 10%   $1,000,000 8% convertible bonds payable   5,000,000 10% bonds payable   6,000,000 Total long-term debt   $12,000,000       Shareholders’ equity     Preferred stock, 6% cumulative, $50 par value, 100,000 shares authorized, 25,000 shares issued and outstanding   $1,250,000 Common stock, $1 par, 10,000,000 shares authorized, 1,000,000 shares issued and outstanding   1,000,000 Additional paid-in capital   4,000,000 Retained earnings   6,000,000 Total shareholders’ equity   $12,250,000 The following transactions have also occurred at Fitzgerald. 1.   Options were granted on July 1, 2019, to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share. 2.   Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019. 3.   The preferred stock was issued in 2019. 4.   There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020. 5.   The 1,000,000 shares of common stock were outstanding for the entire 2020 fiscal year. 6.   Net income for fiscal year 2020 was $1,500,000, and the average income tax rate is 20%. For the fiscal year ended June 30, 2020, calculate the following for Fitzgerald Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.) (a) Basic earnings per share. Basic earnings per share   $   (b) Diluted earnings per share. Diluted earnings per share   $

FINANCIAL ACCOUNTING
10th Edition
ISBN:9781259964947
Author:Libby
Publisher:Libby
Chapter1: Financial Statements And Business Decisions
Section: Chapter Questions
Problem 1Q
icon
Related questions
Question
100%

Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020.

Fitzgerald Pharmaceutical Industries
Selected Balance Sheet Information
June 30, 2020

Long-term debt    
Notes payable, 10%  

$1,000,000

8% convertible bonds payable  

5,000,000

10% bonds payable  

6,000,000

Total long-term debt  

$12,000,000

     
Shareholders’ equity    
Preferred stock, 6% cumulative, $50 par value, 100,000 shares authorized, 25,000 shares issued and outstanding  

$1,250,000

Common stock, $1 par, 10,000,000 shares authorized, 1,000,000 shares issued and outstanding  

1,000,000

Additional paid-in capital  

4,000,000

Retained earnings  

6,000,000

Total shareholders’ equity  

$12,250,000


The following transactions have also occurred at Fitzgerald.

1.   Options were granted on July 1, 2019, to purchase 200,000 shares at $15 per share. Although no options were exercised during fiscal year 2020, the average price per common share during fiscal year 2020 was $20 per share.
2.   Each bond was issued at face value. The 8% convertible bonds will convert into common stock at 50 shares per $1,000 bond. The bonds are exercisable after 5 years and were issued in fiscal year 2019.
3.   The preferred stock was issued in 2019.
4.   There are no preferred dividends in arrears; however, preferred dividends were not declared in fiscal year 2020.
5.   The 1,000,000 shares of common stock were outstanding for the entire 2020 fiscal year.
6.   Net income for fiscal year 2020 was $1,500,000, and the average income tax rate is 20%.


For the fiscal year ended June 30, 2020, calculate the following for Fitzgerald Pharmaceutical Industries. (Round answers to 2 decimal places, e.g. $2.45.)

(a) Basic earnings per share.

Basic earnings per share   $

 


(b) Diluted earnings per share.

Diluted earnings per share   $

 

Expert Solution
trending now

Trending now

This is a popular solution!

steps

Step by step

Solved in 4 steps with 4 images

Blurred answer
Knowledge Booster
Accounting for Long-term liabilities
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
FINANCIAL ACCOUNTING
FINANCIAL ACCOUNTING
Accounting
ISBN:
9781259964947
Author:
Libby
Publisher:
MCG
Accounting
Accounting
Accounting
ISBN:
9781337272094
Author:
WARREN, Carl S., Reeve, James M., Duchac, Jonathan E.
Publisher:
Cengage Learning,
Accounting Information Systems
Accounting Information Systems
Accounting
ISBN:
9781337619202
Author:
Hall, James A.
Publisher:
Cengage Learning,
Horngren's Cost Accounting: A Managerial Emphasis…
Horngren's Cost Accounting: A Managerial Emphasis…
Accounting
ISBN:
9780134475585
Author:
Srikant M. Datar, Madhav V. Rajan
Publisher:
PEARSON
Intermediate Accounting
Intermediate Accounting
Accounting
ISBN:
9781259722660
Author:
J. David Spiceland, Mark W. Nelson, Wayne M Thomas
Publisher:
McGraw-Hill Education
Financial and Managerial Accounting
Financial and Managerial Accounting
Accounting
ISBN:
9781259726705
Author:
John J Wild, Ken W. Shaw, Barbara Chiappetta Fundamental Accounting Principles
Publisher:
McGraw-Hill Education